Thumbnail website _ 1200x675_EssilorLuxottica Announces Agreement to Acquire Espansione Group
December 17, 2024

EssilorLuxottica Announces Agreement to Acquire Espansione Group

EssilorLuxottica’s 2024 shopping spree continues with a move into dry eye and retinal disease treatment. 2024 may be drawing to…

EyePoint Doses First Patient in Second Phase 3 Trial of DURAVYU™️ for Wet AMD
December 13, 2024

EyePoint Doses First Patient in Second DURAVYU™ Phase 3 Trial for Wet AMD

The firm is gathering safety and efficacy evidence for its sustained delivery, selective tyrosine kinase inhibitor nAMD treatment.  EyePoint Pharmaceuticals…

Discover our fascinating content at issuu

explore